Skip to content
value.today
Total raised
$1 M
1 round on record
Latest round
$1 M
Jul 2009
First round on record
Jul 2009
Today
Went public
See the company page

Nephros Inc. is listed today as Nephros, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Nephros Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2021$1 MPrivate placement after listingUnder $2 million

Nephros Inc.: Private sale, Jul 2021

Investors in this round

1 investor had bought by the notice of Jul 14, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Astor · Executive Officer, Director
  • Alisa Lask · Director
  • Arthur Amron · Director
  • Malcolm Person · Director
  • Oliver Spandow · Director
  • Thomas Gwydir · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Nephros, Inc. issued 123,981 shares of its common stock to GenArraytion, Inc. as consideration for the acquisition of substantially all of the assets of GenArraytion, Inc.”

Signed by Andrew Astor, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 14, 2021. Read the notice at the SEC.

equitySEC
May 2019$2 MPrivate placement after listing$2 to $10 million

Nephros Inc.: Private sale, May 2019

Investors in this round

12 investors had bought by the notice of May 21, 2019: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Astor · Executive Officer
  • Daron Evans · Executive Officer, Director
  • Alisa C. Lask · Director
  • Arthur H. Amron · Director
  • Malcolm C. Persen · Director
  • Oliver C. Spandow · Director
  • Paul A. Mieyal · Director
  • Thomas C. Gwydir · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Anticipated payment of executive officer salaries.”

Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed May 21, 2019. Read the notice at the SEC.

equitySEC
Apr 2018$3 MPrivate placement after listing$2 to $10 million

Nephros Inc.: Private sale, Apr 2018

Investors in this round

13 investors had bought by the notice of Apr 18, 2018: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Astor · Executive Officer
  • Daron Evans · Executive Officer, Director
  • Arthur Amron · Director
  • Malcolm Persen · Director
  • Moshe Pinto · Director
  • Paul Mieyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Anticipated payment of executive officer salaries.”

Signed by Andrew Astor, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 18, 2018. Read the notice at the SEC.

equitySEC
Mar 2017$2 MPrivate placement after listing$2 to $10 million

Nephros Inc.: Private sale, Mar 2017

Investors in this round

19 investors had bought by the notice of Mar 27, 2017: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$91,350
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Astor · Executive Officer
  • Daron Evans · Executive Officer, Director
  • Arthur Amron · Director
  • Malcolm Persen · Director
  • Moshe Pinto · Director
  • Paul Mieyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition, the placement agent received warrants to purchase 81,199 shares of common stock.”
  • On the amounts: “The total offering amount and total amount sold include both common stock and warrants to purchase $1218000 of common stock.”
  • On the use of proceeds: “Anticipated payment of executive officer salaries.”

Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 27, 2017. Read the notice at the SEC.

equity, optionsSEC
Jul 2015$1 MPrivate placement after listingUnder $2 million

Nephros Inc.: Private sale, Jul 2015

Investors in this round

1 investor had bought by the notice of Sep 18, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $10 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Astor · Executive Officer
  • Daron Evans · Executive Officer, Director
  • Arthur Amron · Director
  • Malcolm Persen · Director
  • Moshe Pinto · Director
  • Oliver Spandow · Director
  • Paul Mieyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Anticipated payment of executive officer salary.”

Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 18, 2018. Read the notice at the SEC.

equitySEC
May 2015$1 MPrivate placement after listingUnder $2 million

Nephros Inc.: Private sale, May 2015

Investors in this round

26 investors had bought by the notice of May 27, 2015: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daron Evans · Executive Officer, Director
  • Arthur Amron · Director
  • Lawrence Centella · Director
  • Malcolm Persen · Director
  • Matthew Rosenberg · Director
  • Paul Mieyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Anticipated payment of executive officer salary.”

Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed May 27, 2015. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$1 MNo. 1Under $2 million

Nephros Inc.: Raise no. 1, Jul 2009

Investors in this round

8 investors had bought by the notice of Aug 7, 2009: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ermest A. Elgin, III · Executive Officer
  • Gerald J. Kochanski · Executive Officer
  • Arthur H. Amron · Director
  • Dr. Paul A. Mieyal · Director
  • James S. Scibetta · Director
  • Lawrence J. Centella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Gerald J. Kochanski, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 7, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Nephros, Inc., its revenue in fiscal 2025 came from these product and service lines: Royalty and Other Revenues $560,000 (3%), Other Revenue $20,000 (0%).

    Annual report (SEC XBRL) · Dec 2025

  • Nephros Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2021).

    SEC Form D · Jul 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jul 2021

Investors#

No investor of Nephros Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Largest shareholders today

Institutions holding Nephros, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nephros Inc.
NameRoleNamed in
Andrew AstorExecutive officerJul 2021
Daron EvansExecutive officerMay 2019
Ermest A. Elgin, IIIExecutive officerAug 2009
Gerald J. KochanskiExecutive officerAug 2009
Alisa LaskDirectorJul 2021
Andrew AstorDirectorJul 2021
Arthur AmronDirectorJul 2021
Malcolm PersonDirectorJul 2021
Oliver SpandowDirectorJul 2021
Thomas GwydirDirectorJul 2021
Alisa C. LaskDirectorMay 2019
Arthur H. AmronDirectorMay 2019
Daron EvansDirectorMay 2019
Malcolm C. PersenDirectorMay 2019
Oliver C. SpandowDirectorMay 2019
Paul A. MieyalDirectorMay 2019
Thomas C. GwydirDirectorMay 2019
Malcolm PersenDirectorSep 2018
Moshe PintoDirectorSep 2018
Paul MieyalDirectorSep 2018
Lawrence CentellaDirectorMay 2015
Matthew RosenbergDirectorMay 2015
Dr. Paul A. MieyalDirectorAug 2009
James S. ScibettaDirectorAug 2009
Lawrence J. CentellaDirectorAug 2009

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.